Loading...
Loading...
ILMN| Name | Value |
|---|---|
| Revenues | 1,176.0M |
| Cost of Revenue | 444.0M |
| Gross Profit | 732.0M |
| Operating Expense | 808.0M |
| Operating I/L | -88.0M |
| Other Income/Expense | -1.0M |
| Interest Income | 17.0M |
| Pretax | -89.0M |
| Income Tax Expense | 145.0M |
| Net Income/Loss | -234.0M |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, serving customers in research, clinical, and emerging markets. The company offers instruments, consumables, genotyping and sequencing services, cancer detection testing services, and instrument service contracts. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa.
